Jessica Ailani, MD, MedStar Georgetown University Hospital, Georgetown, Washington, DC, discusses the results of the Phase III extension trial (NCT02873221) evaluating ubrogepant for acute migraines. In the extension study, it was found that there were no additional safety concerns when ubrogepant was used repeatedly long term. The ability of ubrogepant to be used at 50 and 100mg as well in combination with triptans as a rescue give the patients more control and flexibility in their treatment. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.